Ophthalmology

The agency granted OCU400 orphan drug designation for additional indications and agreed to a phase 3 trial design for NeoCart.

With several newly approved therapies hitting the market and an overflowing pipeline, the FDA has stepped in to help keep the burgeoning world of biotech on track.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Initial safety data from the PRODYGY study are expected in 2023.

Review top news and interview highlights from the week ending December 2, 2022.

OPGx-001 is the first of Opus Genetics’ gene therapy candidates for treating LCA to enter clinical trials.

The director of clinical research at Sierra Eye Associates discussed unmet needs in patients with wet AMD.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending November 18, 2022.

Editas has paused enrollment in the BRILLIANCE trial after efficacy was only seen in a very small subset of patients.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

4D Molecular Therapeutics plans to initiate enrollment in the phase 2 randomized portion of the study in the first quarter of 2023.

The Genomics and Epigenetic Guided Safe Harbor mapper will aid in the future design of gene-editing therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Among the trial’s high dose cohort, 80% of patients did not require supplemental injections for over 2 years.

Review top news and interview highlights from the week ending November 4, 2022.

Updated data from the ALTITUDE trial were presented at the 55th ARS meeting in Pasadena, CA.

Neurotech has announced updated data from protocol A and B phase 3 studies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Studies have demonstrated positive data that suggest in vivo gene editing will be the future treatment paradigm for retinal diseases.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

As we learn more about genomics and identify more genes tied to rare disorders, the role of genetic counselors will become even more critical.

The grant goes toward developing an innovative approach to gene-agnostically and autonomously regulate pressure.